Literature DB >> 26981172

Human albumin solution for patients with cirrhosis and acute on chronic liver failure: Beyond simple volume expansion.

Christopher Valerio1, Eleni Theocharidou1, Andrew Davenport1, Banwari Agarwal1.   

Abstract

To provide an overview of the properties of human serum albumin (HSA), and to review the evidence for the use of human albumin solution (HAS) in critical illness, sepsis and cirrhosis. A MEDLINE search was performed using the terms "human albumin", "critical illness", "sepsis" and "cirrhosis". The references of retrieved articles were reviewed manually. Studies published between 1980 and 2014 were selected based on quality criteria. Data extraction was performed by all authors. HSA is the main plasma protein contributing greatly to its oncotic pressure. HSA demonstrates important binding properties for endogenous and exogenous toxins, drugs and drug metabolites that account for its anti-oxidant and anti-inflammatory properties. In disease states, hypoalbuminaemia is secondary to decreased HSA production, increased loss or transcapillary leakage into the interstitial space. HSA function can be also altered in disease with reduced albumin binding capacity and increased production of modified isoforms. HAS has been used as volume expander in critical illness, but received criticism due to cost and concerns regarding safety. More recent studies confirmed the safety of HAS, but failed to show any survival benefit compared to the cheaper crystalloid fluids, therefore limiting its use. On the contrary, in cirrhosis there is robust data to support the efficacy of HAS for the prevention of circulatory dysfunction post-large volume paracentesis and in the context of spontaneous bacterial peritonitis, and for the treatment of hepato-renal syndrome and hypervolaemic hyponatraemia. It is likely that not only the oncotic properties of HAS are beneficial in cirrhosis, but also its functional properties, as HAS replaces the dysfunctional HSA. The role of HAS as the resuscitation fluid of choice in critically ill patients with cirrhosis, beyond the established indications for HAS use, should be addressed in future studies.

Entities:  

Keywords:  Cirrhosis; Critical illness; Hepatorenal syndrome; Human albumin solution; Human serum albumin; Large-volume paracentesis; Resuscitation fluid; Spontaneous bacterial peritonitis

Year:  2016        PMID: 26981172      PMCID: PMC4779163          DOI: 10.4254/wjh.v8.i7.345

Source DB:  PubMed          Journal:  World J Hepatol


  68 in total

1.  Oncotic pressure regulates gene transcriptions of albumin and apolipoprotein B in cultured rat hepatoma cells.

Authors:  A Yamauchi; Y Fukuhara; S Yamamoto; F Yano; M Takenaka; E Imai; T Noguchi; T Tanaka; T Kamada; N Ueda
Journal:  Am J Physiol       Date:  1992-08

Review 2.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

3.  Regulation of albumin synthesis and catabolism by alteration of dietary protein.

Authors:  R Kirsch; L Frith; E Black; R Hoffenberg
Journal:  Nature       Date:  1968-02-10       Impact factor: 49.962

4.  Quantitative determination of the stabilizers octanoic acid and N-acetyl-DL-tryptophan in human albumin products.

Authors:  M W Yu; J S Finlayson
Journal:  J Pharm Sci       Date:  1984-01       Impact factor: 3.534

5.  Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials.

Authors:  Mauro Bernardi; Paolo Caraceni; Roberta J Navickis; Mahlon M Wilkes
Journal:  Hepatology       Date:  2012-04       Impact factor: 17.425

6.  Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study.

Authors:  Macarena Simón-Talero; Rita García-Martínez; Maria Torrens; Salvador Augustin; Susana Gómez; Gustavo Pereira; Mónica Guevara; Pere Ginés; Germán Soriano; Eva Román; Jordi Sánchez-Delgado; Roser Ferrer; Juan C Nieto; Pilar Sunyé; Inma Fuentes; Rafael Esteban; Juan Córdoba
Journal:  J Hepatol       Date:  2013-07-19       Impact factor: 25.083

7.  Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality.

Authors:  Rajiv Jalan; Kerstin Schnurr; Rajeshwar P Mookerjee; Sambit Sen; Lisa Cheshire; Stephen Hodges; Vladimir Muravsky; Roger Williams; Gert Matthes; Nathan A Davies
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

8.  Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival.

Authors:  Karl Oettl; Ruth Birner-Gruenberger; Walter Spindelboeck; Hans Peter Stueger; Livia Dorn; Vanessa Stadlbauer; Csilla Putz-Bankuti; Peter Krisper; Ivo Graziadei; Wolfgang Vogel; Carolin Lackner; Rudolf E Stauber
Journal:  J Hepatol       Date:  2013-06-25       Impact factor: 25.083

9.  Defining the role of albumin infusion in cirrhosis-associated hyponatremia.

Authors:  Minhtri K Nguyen; Vahram Ornekian; Liyo Kao; Anthony W Butch; Ira Kurtz
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-05-15       Impact factor: 4.052

Review 10.  Renal dysfunction in cirrhosis is not just a vasomotor nephropathy.

Authors:  Danielle Adebayo; Vincenzo Morabito; Andrew Davenport; Rajiv Jalan
Journal:  Kidney Int       Date:  2014-10-08       Impact factor: 10.612

View more
  11 in total

Review 1.  Antiretroviral Therapy and Alcohol Interactions: X-raying Testicular and Seminal Parameters Under the HAART Era.

Authors:  Oluwatosin O Ogedengbe; Edwin C S Naidu; Onyemaechi O Azu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-04       Impact factor: 2.441

2.  Gasdermin E-derived caspase-3 inhibitors effectively protect mice from acute hepatic failure.

Authors:  Wan-Feng Xu; Quan Zhang; Chu-Jie Ding; Hui-Yong Sun; Yuan Che; Hai Huang; Yun Wang; Jia-Wei Wu; Hai-Ping Hao; Li-Juan Cao
Journal:  Acta Pharmacol Sin       Date:  2020-05-26       Impact factor: 6.150

3.  Association Between Serum Albumin Levels and Obesity and Risk of Developing Chronic Kidney Disease Using Data from the Korean Multi-Rural Communities Cohort (MRCohort) Population Database.

Authors:  Kwang Ho Mun
Journal:  Med Sci Monit       Date:  2021-08-16

4.  A comprehensive validation of HBV-related acute-on-chronic liver failure models to assist decision-making in targeted therapeutics.

Authors:  Yi Shen; Xulin Wang; Sheng Zhang; Gang Qin; Yanmei Liu; Yihua Lu; Feng Liang; Xun Zhuang
Journal:  Sci Rep       Date:  2016-09-16       Impact factor: 4.379

Review 5.  Fluid balance concepts in medicine: Principles and practice.

Authors:  Maria-Eleni Roumelioti; Robert H Glew; Zeid J Khitan; Helbert Rondon-Berrios; Christos P Argyropoulos; Deepak Malhotra; Dominic S Raj; Emmanuel I Agaba; Mark Rohrscheib; Glen H Murata; Joseph I Shapiro; Antonios H Tzamaloukas
Journal:  World J Nephrol       Date:  2018-01-06

Review 6.  Pharmacological Interactions in the Elderly.

Authors:  Emilia Błeszyńska; Łukasz Wierucki; Tomasz Zdrojewski; Marcin Renke
Journal:  Medicina (Kaunas)       Date:  2020-06-28       Impact factor: 2.430

Review 7.  Acute kidney injury spectrum in patients with chronic liver disease: Where do we stand?

Authors:  Wiwat Chancharoenthana; Asada Leelahavanichkul
Journal:  World J Gastroenterol       Date:  2019-07-28       Impact factor: 5.742

8.  Platelet-hemoglobin ratio predicts amputation in patients with below-knee peripheral arterial disease.

Authors:  Nail Burak Ozbeyaz; Gokhan Gokalp; Engin Algul; Haluk Furkan Sahan; Faruk Aydinyilmaz; Ilkin Guliyev; Kamuran Kalkan; Hilal Erken Pamukcu
Journal:  BMC Cardiovasc Disord       Date:  2022-07-28       Impact factor: 2.174

9.  QCM-based assay designs for human serum albumin.

Authors:  Wisnu Arfian A Sudjarwo; Mathias Thomas Dobler; Peter A Lieberzeit
Journal:  Anal Bioanal Chem       Date:  2021-12-23       Impact factor: 4.142

10.  Mycobacterium tuberculosis complex bacteremia among HIV and non-HIV patients in a Mexican tertiary care center.

Authors:  Karla Maria Tamez-Torres; Pedro Torres-Gonzalez; Miguel E Cervera-Hernandez; Barbara Chavez-Mazari; Corazon de Jesus Barrientos-Flores; Miriam Bobadilla-Del-Valle; Alfredo Ponce-de-Leon; Jose Sifuentes-Osornio
Journal:  Braz J Infect Dis       Date:  2018-10-30       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.